Monoclonal antibody successes in the clinic

Nature Biotechnology

Volumn 23, Issue 9, 2005, Pages 1073-1078

  Reichert, Janice M ^a   Rosensweig, Clark J ^b   Faden, Laura B ^a   Dewitz, Matthew C ^b  

^a TUFTS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; INDUSTRIAL MANAGEMENT; MOLECULAR STRUCTURE;

CLINICAL TRIALS; REVENUES; SMALL-MOLECULE DRUGS;

MONOCLONAL ANTIBODIES;

ABCIXIMAB; ADALIMUMAB; AFELIMOMAB; ALEMTUZUMAB; ATLIZUMAB; AUROGRAB; BASILIXIMAB; BEVACIZUMAB; CATUMAXOMAB; CENTOXIN; CERTOLIZUMAB PEGOL; CETUXIMAB; CHIMERIC ANTIBODY; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; IMMUNOLOGIC AGENT; INFLIXIMAB; IPILIMUMAB; MEPOLIZUMAB; METHICILLIN RESISTANT STAPHYLOCCOCUS AUREUS MONOCLONAL ANTIBODY; MISSISSAUGA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; NATALIZUMAB; NIMOTUZUMAB; NUMAX; OKT 3; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; PANITUMUMAB; PEXELIZUMAB; RANIBIZUMAB; RANIBUZIMAB; REMOVAB; RESPIRATORY SYNCYTIAL PNEUMOVIRUS MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZANOLIMUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BIOTECHNOLOGY; CANCER THERAPY; CELL IMMORTALIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; GRAFT REJECTION; GRAM NEGATIVE SEPSIS; HEMOSTASIS; HUMAN; HYBRIDOMA; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; HYBRIDOMAS; IMMUNOTHERAPY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

NEGIBACTERIA; RESPIRATORY SYNCYTIAL VIRUS;

EID: 27144457667     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0905-1073     Document Type: Review

References (14)

1. Reichert, J.M. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19, 819-822 (2001).
2. Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110-118 (2002).
3. Reichert, J. & Pavolu, A. Monoclonal antibodies market. Nat. Rev. Drug Discov. 3, 383-384 (2004).
4. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
5. Milstein, C. The hybridoma revolution: an offshoot of basic research. Bioessays 21, 966-973 (1999).
6. Morrison, S.L. et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851-6855 (1984).
7. Boulianne, G.L. et al. Production of functional chimaeric mouse/human antibody. Nature 312, 643-646 (1984).
8. Cole, S.P., Campling, B.G., Atlaw, T., Kozbor, D. & Roder, J.C. Human monoclonal antibodies. Mol. Cell. Biochem. 62, 109-120 (1984).
9. Carson, D.A. et al. Human lymphocyte hybridomas and monoclonal antibodies. Adv. Immunol. 38, 275-311 (1986).
10. Pasqualini, R. & Arap, W. Hybridoma-free generation of monoclonal antibodies. Proc. Natl. Acad. Sci. USA 101, 257-259 (2004).
11. Inglis, T.J.J. et al. Monoclonal antiendotoxin agent HA-1A (Centoxin). Lancet 341, 303 (1993).
12. Jones, P.T. et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
13. Fleming, T. (ed.). Red Book (Thomson PDR, Montvale, New Jersey, 2004).
14. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 (2004).